Replimune Group (REPL) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Replimune Group (REPL) has outperformed Vor Biopharma (VOR) over the past year, gaining 183.9% versus a loss of 44.4%. Over five years, REPL leads with a -56.2% price change compared with -93.9% for VOR. Replimune Group is the larger company by market cap ($1.24 billion vs $1.11 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REPL | VOR |
|---|---|---|
| Share price | $13.20 | $18.78 |
| Market cap | $1.24B | $1.11B |
| 1-day change | -0.38% | +2.57% |
| YTD return | +35.80% | +43.58% |
| 1-year return | +183.87% | -44.44% |
| 5-year return | -56.22% | -93.93% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-3.15 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.33 | $33.50 |
| 52-week low | $1.50 | $6.50 |
| Distance from 52-week high | -19.17% | -43.94% |
| Average volume | 4.20M | 999.37K |
| Shares outstanding | 94.22M | 59.16M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed VOR by 228.3 percentage points over the past year.
REPL vs VOR FAQ
Which is bigger, Replimune Group or Vor Biopharma?
Replimune Group (REPL) is larger, with a market capitalization of $1.24B compared with $1.11B for Vor Biopharma (VOR).
Which stock has performed better over the past year, REPL or VOR?
REPL returned +183.87% over the past 12 months, compared with -44.44% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are Replimune Group and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.